An experimental Parkinson’s disease treatment called solengepras reduced daily “off” time by about 37 minutes compared with a placebo (inactive treatment) in a phase 3 clinical trial. “Off” time refers to periods when Parkinson’s symptoms return or worsen as medication wears off.
The findings suggest that solengepras could become another treatment option for people who experience motor fluctuations (changes in movement symptoms) despite taking levodopa with or without other Parkinson’s medications.
However, solengepras is not yet approved by the U.S. Food and Drug Administration (FDA). More research and regulatory review are needed.
Solengepras is an experimental once-daily oral medication being studied as an add-on treatment for people with Parkinson’s disease who experience “off” periods. Unlike treatments that directly affect dopamine, solengepras blocks a receptor called GPR6. GPR6 is involved in brain pathways that control movement.
Many Parkinson’s medications work by replacing, boosting, or acting like dopamine, a chemical that helps control movement. Over time, the effects of each dose of levodopa may not last as long, leading to “off” periods when symptoms return.
During “on” periods, medication helps control movement symptoms. During “off” periods, symptoms such as slowness, stiffness, tremor, freezing, fatigue, or anxiety may return. These changes can make everyday activities more difficult.
The phase 3 ARISE trial was an international study involving 341 adults with Parkinson’s disease who experienced motor fluctuations despite taking their usual medications. Participants had an average of 5.65 hours of daily “off” time when the study began.
Participants were randomly assigned to receive 75 milligrams or 150 milligrams of solengepras, or a placebo once daily for 12 weeks. Neither participants nor researchers knew which treatment each person received during the study.
The higher dose met the study’s main goal of reducing daily “off” time.
At week 12, researchers found:
The reduction in “off” time appeared as early as week 2, the first follow-up assessment.
Although the findings are encouraging, they haven’t yet been confirmed through a published, peer-reviewed phase 3 study.
Like all treatments, solengepras can cause side effects (also called adverse events).
The most frequently reported adverse events among people receiving 150 milligrams included:
Some people also experienced dyskinesia.
Across all three treatment groups, 3.5 percent of participants stopped treatment because of an adverse event. No serious adverse events were reported in the 150-milligram group.
These findings provide an early picture of the medication’s safety. But the 12-week trial can’t establish its long-term risks.
For people living with Parkinson’s disease, even relatively short periods of worsening symptoms can disrupt daily routines. The trial suggests that reducing “off” time by about half an hour compared with placebo may offer meaningful relief for some people.
However, the findings have important limitations. The trial lasted only 12 weeks and involved people who already experienced substantial daily “off” time despite taking Parkinson’s medications. It’s not yet clear how well solengepras might work for other groups or how its safety and effectiveness might change with longer use.
The drug’s developer, Cerevance, plans to discuss a potential New Drug Application with the FDA, but solengepras remains investigational.
For now, people experiencing “off” periods can work with their healthcare teams to explore existing ways to manage symptoms. Keeping track of when symptoms occur and how they relate to medication timing may help identify patterns and guide treatment discussions.
If you’re living with Parkinson’s disease and aren’t satisfied with how well your current treatment controls symptoms, or you’re curious about other options, talk with your neurologist about which approaches might best fit your symptoms, needs, and goals.
Get updates directly to your inbox.
Become a member to get even more
This is a member-feature!
Sign up for free to view article comments.
We'd love to hear from you! Please share your name and email to post and read comments.
You'll also get the latest articles directly to your inbox.